Citadel Advisors’s Apollo Endosurgery, Inc. APEN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-13,615
| Closed | -$135K | – | 15764 |
|
|
2023
Q1 | $135K | Buy |
13,615
+3,198
| +31% | +$31.7K | ﹤0.01% | 10805 |
|
|
2022
Q4 | $104K | Sell |
10,417
-55,610
| -84% | -$415K | ﹤0.01% | 11167 |
|
|
2022
Q3 | $363K | Sell |
66,027
-3,780
| -5% | -$21K | ﹤0.01% | 9161 |
|
|
2022
Q2 | $255K | Buy |
69,807
+39,466
| +130% | +$187K | ﹤0.01% | 10182 |
|
|
2022
Q1 | $183K | Sell |
30,341
-43,076
| -59% | -$262K | ﹤0.01% | 11642 |
|
|
2021
Q4 | $619K | Buy |
73,417
+47,225
| +180% | +$413K | ﹤0.01% | 9149 |
|
|
2021
Q3 | $237K | Sell |
26,192
-15,048
| -36% | -$129K | ﹤0.01% | 11597 |
|
|
2021
Q2 | $335K | Buy |
41,240
+13,809
| +50% | +$94.8K | ﹤0.01% | 11002 |
|
|
2021
Q1 | $151K | Buy |
+27,431
| New | +$136K | ﹤0.01% | 12029 |
|
|
2020
Q1 | – | Sell |
-10,758
| Closed | -$31K | – | 10391 |
|
|
2019
Q4 | $31K | Buy |
+10,758
| New | +$31.2K | ﹤0.01% | 8861 |
|
|
2016
Q2 | – | Sell |
-1,058
| Closed | -$15K | – | 7576 |
|
|
2016
Q1 | $15K | Buy |
1,058
+33
| +3% | +$458 | ﹤0.01% | 6552 |
|
|
2015
Q4 | $18K | Buy |
1,025
+360
| +54% | +$6.07K | ﹤0.01% | 8013 |
|
|
2015
Q3 | $10K | Buy |
+665
| New | +$12.7K | ﹤0.01% | 8478 |
|
Citadel Advisors's APEN Position: Q2 2023 in Review
Citadel Advisors sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 13,615 shares — an estimated $135K sold.
Citadel Advisors first reported a position in APEN in Q3 2015 and held it in 13 quarters. The position peaked at $619K in Q4 2021. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.
- Citadel Advisors reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 13,615 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $135K.
- Citadel Advisors first reported a position in Apollo Endosurgery, Inc. in Q3 2015 and held it in 13 quarters.
- Citadel Advisors's Apollo Endosurgery, Inc. position peaked at $619K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.